Drug Profile
Ralpancizumab
Alternative Names: PF-05335810; PF-5335810; RN 317Latest Information Update: 05 Mar 2014
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 28 Feb 2014 Discontinued - Phase-I for Hypercholesterolaemia in USA (IV)
- 28 Feb 2014 Discontinued - Phase-I for Hypercholesterolaemia in USA (SC)
- 16 Sep 2013 Pfizer completes a phase I trial in Hypercholesterolaemia in USA (NCT01720537)